Pharmacokinetics of Serum Fluconazole by a Solid Phase Extraction-Hplc

XIA Chun-hua,ZHANG Xin-jing,LI Yan-yan,XIONG Yu-qing

DOI: https://doi.org/10.3321/j.issn:1003-3734.2005.08.031

2005-01-01

Abstract:Objective:To compare the pharmacokinetic profiles and bioequivalence of fluconazole capsules by an established HPLC. Methods:An open-label, randomized and crossover dose clinical study recruited 18 male volunteers, who were randomly treated with a single crossover dose of test or reference fluconazole capsules (150 mg each). The plasma samples (1.0 mL) from the volunteers were loaded on to a C_ 18 cartridges activated with methanol. The cartridge was eluted with 1.0 mL aqueous solutions containing 20% methanol, and subsequently eluted with 0.2 mL methanol. 20 μL of the eluate was analyzed by HPLC, which consisted of a Diamonsil ODS C_ 18 column (150 mm×4.6 mm 5 μm), the mobile phase made of 0.01 mol·L -1 KH_2PO_4 solution (pH=5.0, adjusted with H_3PO_4)-acetonitrile (75∶25) with a flow rate of 1.0 mL·min -1 , and detection at 267 nm.Results:The calibrated linear curve was in the range of 0.1～6.4 mg·L -1 (r=0.999 9). The detection limit was 0.1 mg·L -1 and the recovery was 95.7%～108.0%. The mean within-day and among-day RSD were less than 15%; the P value showed no statistical difference between the test and reference capsules. The relative bioavailability of the test capsules was (105.7±12.6)%.Conclusion:The sensitive, reproducible and specific HPLC confirmed that the test fluconazole capsules were bioequivalent to the reference capsules.